Objective:
To evaluate the efficacy and safety of the vorolanib intravitreal insert (EYP-1901) in diabetic macular edema (DME) through the Phase 2 VERONA clinical trial.
Key Findings:
- EYP-1901 met its primary endpoint, showing extended time to first supplemental treatment compared to aflibercept.
- 73% of patients in the vorolanib 2.7 mg arm remained supplement-free up to Week 24.
- Clinically meaningful improvement in BCVA of around 7 letters was reported at Week 24.
Interpretation:
Vorolanib's mechanism of action as a TKI may provide complementary benefits to traditional anti-VEGF therapies, potentially enhancing treatment outcomes in DME.
Limitations:
- The study was limited to a Phase 2 trial, which may not fully predict Phase 3 outcomes.
- The long-term effects and safety profile of vorolanib in a larger population remain to be established.
Conclusion:
Vorolanib shows promise in improving visual outcomes and reducing treatment burden in DME, warranting further investigation in Phase 3 trials.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.